Drugs that contain Letrozole; Ribociclib Succinate

1. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324225 NOVARTIS Pyrrolopyrimidine compounds and their uses
Jun, 2028

(5 years from now)

US8415355 NOVARTIS Pyrrolopyrimidine compounds and their uses
Aug, 2029

(6 years from now)

US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

US9193732 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
Nov, 2031

(9 years from now)

CN103201275A NOVARTIS Salt Of 7-Cyclopentyl-2(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo [2,3-D] Pyrimidine-6-Carboxylic Acid Dimethylamide And Process Of Making Thereof
Dec, 2015

(6 years ago)

CN103788100A NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Jun, 2017

(5 years ago)

CN101594871A NOVARTIS Pyrrolopyrimidine Compounds And Use Thereof
May, 2027

(4 years from now)

CN101594871B NOVARTIS Pyrrolopyrimidine Compounds And Use Thereof
May, 2027

(4 years from now)

CN102186856B NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

CN102186856A NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

CN105384741A NOVARTIS Salt Of Cell Cycle Regulatory Proteins Cyclin-Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

CN105384741B NOVARTIS A Salt Of A Cell Cycle Regulation Protein Dependent Kinase Inhibitor And Preparation Method Thereof
Nov, 2031

(9 years from now)

IN200809406P1 NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

IN283133B NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

EP2029145A2 NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

EP2029145B1 NOVARTIS Pyrrolopyrimidine Compounds And Their Uses
May, 2027

(4 years from now)

EP2331547A1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2331547B1 NOVARTIS Pyrrolopyrimidine Compounds As Cdk Inhibitors
Aug, 2029

(6 years from now)

EP2638030B1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

EP2638030A1 NOVARTIS Succinate Salt Of 7-Cyclopentyl-2 -(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof
Nov, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9416136 NOVARTIS Pyrrolopyrimidine compounds and their uses Aug, 2029

(6 years from now)

US8962630 NOVARTIS Pyrrolopyrimidine compounds and their uses Dec, 2029

(7 years from now)

US9868739 NOVARTIS Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof Nov, 2031

(9 years from now)

US10799506 NOVARTIS Ribociclib tablet Apr, 2036

(13 years from now)

Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;EQ 200MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.